[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Markets Direct: Market Research Reports

Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.

A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.

The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.

With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.

Under the supervision of skillful managers and experts, business analysts produce reports that include:

  • Product portfolio
  • Potentially strong market reviews
  • Competitive analytics
  • Prospect partners
  • Mergers and acquisitions project data
  • Latest trends across a particular industry area
  • Research and development strategies
  • The analysis of new customers
  • A set of remedial measures for projects

They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.

Publications found: 5,853
Sort by:

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Pipeline Review, H1 2018

US$ 3,500.00

... Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 136 pages

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Pipeline Review, H1 2018

US$ 3,500.00

... Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 44 pages

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2018

US$ 3,500.00

... Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 67 pages

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H1 2018

US$ 3,500.00

... Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 48 pages

Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Pipeline Review, H1 2018

US$ 3,500.00

... Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 79 pages

Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) - Pipeline Review, H1 2018

US$ 3,500.00

... Integrin Beta 1 (Fibronectin Receptor Subunit Beta or Glycoprotein Iia or VLA 4 Subunit Beta or CD29 or ITGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 56 pages

Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) - Pipeline Review, H1 2018

US$ 3,500.00

... Phenylalanine 4 Hydroxylase (Phe 4 Monooxygenase or PAH or EC 1.14.16.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 30 pages

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2018

US$ 3,500.00

... Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 48 pages

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H1 2018

US$ 3,500.00

... T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products based ...

May 2018 48 pages

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2018

US$ 3,500.00

... T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 70 pages

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) development landscape Develop and design ...

May 2018 83 pages

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H1 2018

US$ 3,500.00

... Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 102 pages

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H1 2018

US$ 3,500.00

... Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 107 pages

Wilms Tumor Protein (WT33 or WT1) - Pipeline Review, H1 2018

US$ 3,500.00

... Wilms Tumor Protein (WT33 or WT1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 65 pages

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018

US$ 3,500.00

... Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 155 pages

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2018

US$ 2,000.00

... Polyarticular Juvenile Idiopathic Arthritis (PJIA) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects. The guide covers therapeutics under Development ...

May 2018 79 pages

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Pipeline Review, H1 2018

US$ 3,500.00

... Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 123 pages

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) development landscape Develop ...

May 2018 66 pages

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) development landscape Develop and design ...

May 2018 63 pages

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) development landscape Develop and design ...

May 2018 77 pages

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2018

US$ 3,500.00

... Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 129 pages

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Pipeline Review, H1 2018

US$ 3,500.00

... also reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics development with respective ...

May 2018 74 pages

Toll Like Receptor 3 (CD283 or TLR3) - Pipeline Review, H1 2018

US$ 3,500.00

... Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 67 pages

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H1 2018

US$ 3,500.00

... Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 75 pages

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2018

US$ 3,500.00

... Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 132 pages

Q Fever - Pipeline Review, H1 2018

US$ 2,000.00

... . The Q Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Q Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

May 2018 38 pages

Interleukin 1 (IL1) - Pipeline Review, H1 2018

US$ 3,500.00

... and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape Develop and design in-licensing and ...

May 2018 106 pages

NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Pipeline Review, H1 2018

US$ 3,500.00

... identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) development landscape Develop ...

May 2018 44 pages

T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) - Pipeline Review, H1 2018

US$ 3,500.00

... T Lymphocyte Activation Antigen CD86 (Activation B7-2 Antigen or CTLA 4 Counter Receptor B7.2 or CD86) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 64 pages

Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) development landscape Develop ...

May 2018 42 pages

5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - Pipeline Review, H1 2018

US$ 3,500.00

... 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

May 2018 66 pages

Radiation Injury - Pipeline Review, H1 2018

US$ 2,000.00

... releases. The Radiation Injury (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...

April 2018 46 pages

Premenstrual Syndrome - Pipeline Review, H1 2018

US$ 2,000.00

... releases. The Premenstrual Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Premenstrual Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

April 2018 32 pages

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) development landscape ...

April 2018 41 pages

Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) development ...

April 2018 130 pages

Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H1 2018

US$ 3,500.00

... Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 52 pages

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H1 2018

US$ 3,500.00

... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) development landscape Develop and design ...

April 2018 81 pages

Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) development landscape Develop and ...

April 2018 106 pages

Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H1 2018

US$ 3,500.00

... Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 41 pages

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2018

US$ 3,500.00

... Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 71 pages

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H1 2018

US$ 3,500.00

... Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 69 pages

Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) development landscape Develop ...

April 2018 50 pages

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... molecule type. It also reviews key players involved in Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics development with respective active and ...

April 2018 34 pages

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H1 2018

US$ 3,500.00

... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) development ...

April 2018 37 pages

Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H1 2018

US$ 3,500.00

... Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...

April 2018 55 pages

Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) - Pipeline Review, H1 2018

US$ 3,500.00

... players involved in Mitogen Activated Protein Kinase 14 (Cytokine Suppressive Anti Inflammatory Drug Binding Protein or Mitogen Activated Protein Kinase p38 Alpha or MAP Kinase MXI2 or MAX Interacting Protein 2 or Stress Activated Protein Kinase 2a or MAPK14 or EC 2.7.11.24) targeted therapeutics development ...

April 2018 69 pages

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H1 2018

US$ 3,500.00

... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) development landscape Develop and ...

April 2018 61 pages

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018

US$ 3,500.00

... players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) development ...

April 2018 98 pages

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2018

US$ 2,000.00

... (Clostridium difficile Associated Disease) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under ...

April 2018 202 pages

Thrombotic Thrombocytopenic Purpura - Pipeline Review, H1 2018

US$ 2,000.00

... . The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...

April 2018 61 pages

Filters

Search

Categories

2,264
2,910
126
9
6
1
1
1
4
522
3
6

Publishers

5,853

Regions

5,853

Price

Date

Pages

Offers